Septerna, Inc. (NASDAQ:SEPN - Get Free Report)'s stock price traded up 8.4% during mid-day trading on Monday . The stock traded as high as $26.43 and last traded at $26.31. 52,213 shares were traded during mid-day trading, a decline of 85% from the average session volume of 337,603 shares. The stock had previously closed at $24.28.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on SEPN shares. TD Cowen began coverage on shares of Septerna in a research note on Tuesday, November 19th. They set a "buy" rating on the stock. Cantor Fitzgerald assumed coverage on Septerna in a research report on Tuesday, November 19th. They set an "overweight" rating and a $50.00 price target on the stock. JPMorgan Chase & Co. started coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an "overweight" rating and a $38.00 price target on the stock. Finally, Wells Fargo & Company initiated coverage on Septerna in a research report on Tuesday, November 19th. They set an "overweight" rating and a $43.00 price objective for the company.
Get Our Latest Stock Report on SEPN
Septerna Price Performance
Insiders Place Their Bets
In related news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of Septerna stock in a transaction dated Monday, October 28th. The stock was acquired at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the completion of the transaction, the insider now directly owns 6,215,591 shares of the company's stock, valued at $111,880,638. This trade represents a 6.34 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
See Also
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
